Recent reports confirm a heartbreaking increase in cough syrup deaths in Madhya Pradesh’s Chhindwara district. The toll has tragically risen to 16 children, two more young lives lost after consuming a contaminated cough syrup. Consequently, families and the community demand answers and accountability. This incident highlights critical issues in drug quality control, especially concerning paediatric medications.
Rising Toll: Chhindwara Records More Cough Syrup Deaths
Two additional children from Chhindwara, undergoing treatment for kidney failure after ingesting contaminated cough syrup, have unfortunately passed away. This brings the total number of fatalities in the district to 16, as confirmed by an official on Tuesday. One girl’s death was reported today, adding to the tragic count. Previously, the state government acknowledged the deaths of 14 children in Chhindwara, who reportedly consumed ‘Coldrif’ cough syrup. Samples of this syrup showed toxic contents.
Jayusha Yaduvanshi, a two-year-old from Junnardeo, died on Tuesday at a government hospital in Nagpur. Dhani Deharia, a two-and-a-half-year-old from Bhariyadhana village in Tamiablock, also passed away on Monday while receiving treatment at Nagpur Medical College. Her family asserts her health deteriorated rapidly, leading to kidney failure, after she took the doctor-prescribed cold syrup. Furthermore, six other children from Chhindwara remain hospitalized in Nagpur, with five in critical condition.
Investigation and Regulatory Actions Underway
The state government has taken swift action following these devastating cough syrup deaths. Authorities suspended two drug inspectors and a deputy director of the Food and Drug Administration (FDA) on Monday. The state’s drug controller also faced transfer amid an ongoing investigation.
Dr. Praveen Soni, a Chhindwara-based physician, was arrested for alleged negligence in prescribing the contaminated syrup. Moreover, a case has been registered against Sresan Pharma, the Tamil Nadu-based company manufacturing ‘Coldrif’ cough syrup. The Madhya Pradesh Police have established a Special Investigation Team (SIT) to probe these fatalities. Laboratory tests confirmed that samples of ‘Coldrif’ syrup contained high levels of diethylene glycol (DEG), a toxic industrial solvent, far exceeding permissible limits. Reports indicate the contamination was as high as 46.28% or 48.6%, significantly above the 0.1% limit.
Following these findings, several states, including Madhya Pradesh, Tamil Nadu, Punjab, and Maharashtra, immediately banned the sale of ‘Coldrif’ syrup. Inspections at Sresan Pharma’s manufacturing site revealed gross violations, including unhygienic conditions, rusted equipment, and lack of quality assurance. This further emphasizes the urgent need for stringent regulatory oversight in drug manufacturing across India. The Union Health Ministry has also advised rational use of cough syrups for children, promoting judicious prescribing. This case underscores the critical importance of understanding paediatric health and medication safety.
Frequently Asked Questions
Q1: How many children have died in the Chhindwara cough syrup incident?
Sixteen children have died in Madhya Pradesh’s Chhindwara district after consuming contaminated cough syrup.
Q2: What was the cause of death for these children?
The children died from kidney failure (renal failure) due to a toxic chemical, diethylene glycol (DEG), found in the ‘Coldrif’ cough syrup they consumed. This highlights the critical need for professionals to be aware of drug composition and potential toxicities, a key aspect of safe prescribing practices.
Q3: What actions have authorities taken in response to these deaths?
Authorities have suspended drug inspectors, transferred the drug controller, arrested the prescribing doctor, and filed a case against the manufacturer, Sresan Pharma. A Special Investigation Team (SIT) is probing the incident, and the syrup has been banned in multiple states. This complex investigation and regulatory response could be further examined within the context of emergency medicine and public health policy.
References
- Cough syrup deaths: toll in MP’s Chhindwara rises to 16 as two more kids die – ETHealthworld
- Police launch manslaughter probe into India’s cough syrup deaths | The Straits Times
- India probes possible cough syrup link to deaths of at least nine children – Al Jazeera
- Six children die in Chhindwara as toxic cough syrup triggers kidney failure – Newsonair
- Cough syrup deaths: Three officials suspended in Madhya Pradesh – The Hindu
- SIT to probe death of 14 children in MP; Doctor held, ‘toxic’ cough syrup maker booked
- Punjab becomes latest state to ban ‘Coldrif’ cough syrup after 14 children die in Madhya Pradesh – The Economic Times
- Renal failure, zero urine output: ‘Killer’ Coldrif syrups leaves 6 kids dead at Nagpur hospital; 14 still critical – Times of India
- What is the toxic DEG found in Coldrif cough syrup: All you need to know | Health News
- India begins criminal action against cough-syrup maker linked to deaths of 14 children
- Illegal chemicals, 350 violations: Inside factory that made ‘killer’ cough syrup – India Today
- Cough syrup deaths: Toll in Madhya Pradesh’s Chhindwara rises to 16 as two more kids die
- SC petition demands CBI probe into deaths of 14 children from contaminated cough syrup in MP – Pharmabiz.com
- Cough syrup tragedy: Madhya Pradesh bans Coldrif as kids’ death toll rises to 11; test report confirms poisonous chemical – The Times of India
- Chhindwara cough syrup case: Exclusive For weeks, as children died of cough syrup in Madhya Pradesh’s Parasia, officials probed in the dark – The Indian Express
- Syrup death toll mounts to 14 in Madhya Pradesh; govt. doctor held for prescribing adulterated syrup – The Hindu
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.